Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 8, 2007, Pages 907-912

  Christensen, S ^a   Riis, A ^a   Norgaard M ^a   Thomsen, R W ^a   Sorensen H T ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CONTROLLED STUDY; DATA BASE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; ULCER PERFORATION; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; MALE; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION;

EID: 34047156584     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03274.x     Document Type: Article

References (25)

1. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
3. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32: 25-32.
4. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346: 498-505.
5. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165: 171-7.
6. Nørgård B, Pedersen L, Johnsen SP, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 817-25.
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8, 2.
8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
9. Lim CH, Heatley RV. Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United Kingdom. Postgrad Med J 2005; 81: 252-4.
10. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331: 1310-6.
11. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004; 328: 1415-6.
12. Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 2398-9.
13. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-8.
14. Christensen S, Riis A, Nørgaard M, et al. Perforated peptic ulcer: use of preadmission oral glucocorticoids and 30-day mortality. Aliment Pharmacol Ther 2006; 23: 45-52.
15. Thomsen RW, Riis A, Christensen S, Nørgaard M, Sørensen HT. Diabetes and 30-day mortality from peptic ulcer bleeding and perforation: a Danish population-based cohort study. Diabetes Care 2006; 29: 805-10.
16. Agresti A. Categorical Data Analysis. New York: John Wiley and Sons, 1990: 100-102.
17. Cattaruzzi C, Troncon MG, Agostinis L, Garcia Rodriguez LA. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 1999; 52: 499-502.
18. Nickelsen TN. Data validity and coverage in the Danish National Health Registry a literature review. .Ugeskr Laeger 2001; 31: 164.
19. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol 2006; 101: 945-53.
20. The Danish Medicines Agency. Medicinal Product Statistics 1996-2000. Available at: http://www.dkma.dk. Last accessed September 2006.
21. Morgenstern H. Ecologic studies in epidemiology: concepts, principles, and methods. Annu Rev Public Health 1995; 16: 61-81.
22. Xia B, Xia HH, Ma CW, et al. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther 2005; 22: 243-9.
23. Arents NL, Thijs JC, van Zwet AA, Kleibeuker JH. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur J Gastroenterol Hepatol 2004; 16: 779-83.
24. Danish Cancer Society. Available at: http://www.cancer.dk/tobak/. 2006(Internet Communication).
25. Mamdani M. Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors? Expert Opin Drug Saf 2005; 4: 591-8.